PROPHASE LABS INC. DL-001

UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following the expiration of the initial 180 calendar days period to regain compliance on June 24, 2025. NASDAQ stated that it based its determination to grant the extension based on the Company meeting all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement.» Mehr auf globenewswire.com

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States» Mehr auf globenewswire.com

Squarepoint Ops LLC bought a new stake in shares of ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 52,394 shares of the company’s stock, valued at approximately $40,000. Squarepoint Ops LLC owned about 0.22% of ProPhase Labs as of its most recent filing with the SEC. A number of other large investors have also recently bought and sold shares of the stock. Warberg Asset Management LLC purchased a new position in shares of ProPhase Labs during the 4th quarter worth $77,000. Renaissance Technologies LLC lifted its stake in shares of ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after purchasing an additional 71,375 shares during the period. Perritt Capital Management Inc lifted its stake in shares of ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after purchasing an additional 107,068 shares during the period. Geode Capital Management LLC lifted its stake in shares of ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after purchasing an additional 42,793 shares during the period. Finally, HighTower Advisors LLC lifted its stake in shares of ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after purchasing an additional 57,736 shares during the period. Institutional investors and hedge funds own 9.45% of the company’s stock. ProPhase Labs Trading Down 1.9% Shares of ProPhase Labs stock opened at $0.35 on Wednesday. ProPhase Labs, Inc. has a fifty-two week low of $0.22 and a fifty-two week high of $4.84. The firm has a market cap of $14.54 million, a PE ratio of -0.28 and a beta of -0.43. The business’s fifty day moving average is $0.32 and its two-hundred day moving average is $0.46. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs (NASDAQ:PRPH – Get Free Report) last issued its quarterly earnings results on Tuesday, May 20th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.06. ProPhase Labs had a negative return on equity of 62.92% and a negative net margin of 217.64%. The company had revenue of $1.43 million for the quarter, compared to analyst estimates of $2.45 million. Analysts anticipate that ProPhase Labs, Inc. will post -1.27 earnings per share for the current year. Analysts Set New Price Targets Separately, Wall Street Zen assumed coverage on ProPhase Labs in a research note on Tuesday, February 25th. They set a “sell” rating on the stock. Get Our Latest Analysis on PRPH ProPhase Labs Company Profile (Free Report) ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. See Also Five stocks we like better than ProPhase Labs Low PE Growth Stocks: Unlocking Investment Opportunities AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway How Investors Can Find the Best Cheap Dividend Stocks Casey’s Surges on Strong Q4, More Gains Likely Ahead 3 Stocks to Consider Buying in October Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding PRPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report).» Mehr auf defenseworld.net